Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Aduro_Biotech,_Inc.
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 |
| gptkbp:focus |
gptkb:vaccine
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:founder |
gptkb:Stephen_Isaacs
|
| gptkbp:headquarters |
gptkb:government_agency
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aduro Biotech Germany
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co. |
| gptkbp:products |
gptkb:ADU-S100
ADU-CLD |
| gptkbp:research_focus |
gptkb:healthcare_organization
|
| gptkbp:technology |
STING pathway
LADD platform |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.adurobiotech.com
|